• Home
  • Search Results
  • Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action.

Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action.

Journal of thrombosis and haemostasis : JTH (2014-06-20)
P Patrignani, S Tacconelli, E Piazuelo, L Di Francesco, M Dovizio, C Sostres, E Marcantoni, P Guillem-Llobat, P Del Boccio, M Zucchelli, C Patrono, A Lanas
ABSTRACT

Even though the acetylation of platelet cyclooxygenase (COX)-1 at serine-529 is the direct mechanism of action of low-dose aspirin, its antiplatelet effect has been characterized using indirect indexes of COX-1 activity. We performed a clinical study with enteric-coated low-dose aspirin (EC-aspirin), in healthy subjects, to evaluate the effects on the extent and duration of platelet COX-1 acetylation, using a novel proteomic strategy for absolute protein quantification (termed AQUA), as compared with traditional pharmacokinetic and pharmacodynamic parameters. In a phase I, single-arm, open-label study of EC aspirin (100 mg day(-1) ) administered to 24 healthy subjects, we compared, over a 24 h-period on day 1 and 7, % platelet acetylated COX-1 (AceCOX-1) with traditional pharmacokinetic and pharmacodynamics [i.e. serum thromboxane (TX) B2 , platelet function by monitoring CEPI(collagen/epinephrine) closure time (CT) using whole-blood PFA-100 and urinary excretion of 11-dehydro-TXB2 ] parameters. Acetylation of platelet COX-1 was measurable before detection of aspirin levels in the systemic circulation and increased in a cumulative fashion upon repeated dosing. After the last dose of EC-aspirin, %AceCOX-1, serum TXB2 and CEPI-CT values were maximally and persistently modified throughout 24 h; they averaged 76 ± 2%, 99.0 ± 0.4% and 271 ± 5 s, respectively. EC-aspirin caused 75% reduction in urinary 11-dehydro-TXB2 excretion. After chronic dosing with aspirin, the pharmacokinetics of acetylsalicylic acid was completely dissociated from pharmacodynamics. The demonstrated feasibility of quantifying the extent and duration of platelet COX-1 acetylation will allow characterizing the genetic, pharmacokinetic and pharmacodynamic determinants of the inter-individual variability in the antiplatelet response to low-dose aspirin as well as identifying extra-platelet sites of drug action.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Salicylic acid, ACS reagent, ≥99.0%
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥98.5% (GC)
Sigma-Aldrich
Sodium fluoride, ACS reagent, ≥99%
Supelco
Salicylic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Salicylic acid, suitable for plant cell culture
Sigma-Aldrich
Salicylic acid, ≥99%, FG
Sigma-Aldrich
Sodium fluoride, BioXtra, ≥99%
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥99.0% (T)
Sigma-Aldrich
Salicylic acid, puriss. p.a., ≥99.0% (T)
Supelco
Sodium Fluoride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium fluoride, 99.99% trace metals basis
Supelco
Fluoride ion solution for ISE, 0.1 M F-, analytical standard (for ion-selective electrodes)
Sigma-Aldrich
Salicylic acid, BioXtra, ≥99.0%
Sigma-Aldrich
Sodium fluoride 0.5 M solution
Sigma-Aldrich
Sodium fluoride, anhydrous, powder, 99.99% trace metals basis
Sigma-Aldrich
Salicylic acid, meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (calc. to the dried substance)
Sigma-Aldrich
Sodium fluoride, ReagentPlus®, ≥99%
Sigma-Aldrich
Sodium fluoride solution
Sigma-Aldrich
Salicylic acid, ReagentPlus®, ≥99%
USP
Salicylic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Sodium fluoride, puriss., 98.5-100.5% (calc. to the dried substance), meets analytical specification of Ph. Eur., BP, USP
Sigma-Aldrich
Sodium fluoride, BioReagent, suitable for insect cell culture, ≥99%
Supelco
Salicylic acid, certified reference material, TraceCERT®
Salicylic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Salicylic acid, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®